• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridine carboxaldehydes

Recent Advances in the Application of 3-Bromo-2-chloropyridine-4-carboxaldehyde (CAS: 1227602-82-5) in Chemical Biology and Pharmaceutical Research

3-Bromo-2-chloropyridine-4-carboxaldehyde (CAS: 1227602-82-5) has emerged as a versatile building block in medicinal chemistry and chemical biology, particularly in the synthesis of novel heterocyclic compounds with potential therapeutic applications. Recent studies have highlighted its utility as a key intermediate in the development of kinase inhibitors, antiviral agents, and other bioactive molecules. This research brief synthesizes the latest findings on this compound, focusing on its synthetic applications, mechanistic insights, and pharmacological potential.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's role in the synthesis of potent BTK (Bruton's tyrosine kinase) inhibitors. Researchers utilized 3-Bromo-2-chloropyridine-4-carboxaldehyde as a crucial intermediate to develop novel covalent inhibitors showing improved selectivity profiles against off-target kinases. The study reported IC50 values in the low nanomolar range for lead compounds derived from this scaffold, with promising results in B-cell malignancy models.

In the field of antiviral research, a recent ACS Infectious Diseases publication (2024) described the compound's application in developing broad-spectrum antiviral agents. The aldehyde functionality of 3-Bromo-2-chloropyridine-4-carboxaldehyde enabled efficient conjugation with various nucleophilic pharmacophores, yielding compounds with activity against both RNA and DNA viruses. Particularly noteworthy was the discovery of derivatives showing dual inhibitory activity against SARS-CoV-2 main protease and human coronavirus 229E, suggesting potential for pandemic preparedness.

From a synthetic chemistry perspective, advances in transition metal-catalyzed cross-coupling reactions have expanded the utility of this compound. A Nature Communications paper (2023) reported a novel palladium-catalyzed carbonylative coupling of 3-Bromo-2-chloropyridine-4-carboxaldehyde with arylboronic acids, enabling efficient access to pyridine-based α-ketoamides - a privileged structure in drug discovery. The methodology demonstrated excellent functional group tolerance and scalability, with yields exceeding 85% in most cases.

The compound's unique reactivity pattern has also attracted attention in chemical biology. Recent work published in Chemical Science (2024) utilized 3-Bromo-2-chloropyridine-4-carboxaldehyde as a bifunctional linker for protein conjugation, capitalizing on both the aldehyde and halogen moieties for sequential bioconjugation strategies. This approach enabled the development of homogeneous antibody-drug conjugates with precise drug-to-antibody ratios, addressing a major challenge in ADC therapeutics.

Looking forward, the diverse applications of 3-Bromo-2-chloropyridine-4-carboxaldehyde suggest continued importance in pharmaceutical research. Current challenges include further optimization of its derivatization protocols and exploration of its potential in emerging areas such as targeted protein degradation and covalent inhibitor design. The compound's commercial availability (purity >98% from major suppliers) and well-characterized properties position it as a valuable tool for medicinal chemistry programs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)